Status:
RECRUITING
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
Lead Sponsor:
AbbVie
Conditions:
Moderate to Severe Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care This is a mono-c...
Eligibility Criteria
Inclusion
- Current or Past participants with a confirmed diagnosis of moderate to severe active RA upon judgement of the treating physician.
- Physician decision on participant treatment with Upadacitinib (UPA) or tumor necrosis factor inhibitor (TNFi) must have been reached prior to and independently of recruitment in the study
- UPA or TNFi prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies
Exclusion
- Participation in a clinical trial with an investigational drug (within a minimum of 30 days or 5 half-lives of the investigational drug \[whichever is longer\] prior to baseline)
- Prior treatment with Upadacitinib
- Prior treatment with the same tumor necrosis factor inhibitor as the one prescribed for this study
Key Trial Info
Start Date :
November 7 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
678 Patients enrolled
Trial Details
Trial ID
NCT06712628
Start Date
November 7 2024
End Date
December 1 2028
Last Update
February 17 2026
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Gemeinschaftspraxis Innere Medizin/Rheumatologie /ID# 278584
Freiburg im Breisgau, Baden-Wurttemberg, Germany, 79098
2
Rheumapraxis Heidelberg /ID# 276475
Heidelberg, Baden-Wurttemberg, Germany, 69120
3
Rheumapraxis Haas Tübingen /ID# 275536
Tübingen, Baden-Wurttemberg, Germany, 72072
4
Rheumapraxis Ulm Dr. med. Nadia Rinaldi /ID# 276293
Ulm, Baden-Wurttemberg, Germany, 89073